Latest News

Slovenia ‘lights up’ during Blood Cancer Awareness Month

This September, our Slovenian member organisation, Društvo BKB, once again marked Blood Cancer Awareness Month and European Myeloma Day, with a wide range of activities dedicated to raising awareness and supporting patients across Slovenia. They organised 12 information stands in health centres, hospitals, and at the University Medical Centres in Ljubljana and Maribor. A special…

Read more

Serbia marks European Myeloma Day with a packed September

Throughout September, the Multiple Myeloma Patient Association of Serbia (MMPAS) marked Blood Cancer Awareness Month with a powerful and heartfelt series of activities across the country — especially in smaller towns, where awareness of multiple myeloma remains extremely low. Guided by empathy and driven by purpose, they launched two national campaigns focused on informing, educating,…

Read more

Watch our Webinar on myeloma and infections

We held our latest webinar on September 11th, called Myeloma and infection: clinical and lived perspectives for myeloma patients, carers and advocates. Jackie Quinn, Myeloma Clinical Nurse Specialist, Belfast Trust presented on how myeloma and treatments increase infection risk, covering immunisations, bispecific antibody risks, and preventive medications. Mimi Quinn, myeloma patient from Ireland shared her personal…

Read more

Myeloma and infection: clinical and lived perspectives webinar

Myeloma Patients Europe (MPE) will host a webinar on “Myeloma and infection: clinical and lived perspectives” on Thursday, 11th September 2025 from 17:00 – 18:00 CEST. Aimed at myeloma patients, carers and patient advocates, the webinar will feature presentations on infection risk and prevention in myeloma, and a patient’s experiences of infection in myeloma. Jackie Quinn,…

Read more

The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patients

The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are eligible for autologous stem cell transplant.  The decision follows an earlier positive recommendation of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP…

Read more

May 2026

MO
TU
WE
TH
FR
SA
SU
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Events for 1st May
No Events
Events for 2nd May
No Events
Events for 3rd May
No Events
Events for 4th May
No Events
Events for 5th May
No Events
Events for 6th May
No Events
Events for 7th May
No Events
Events for 8th May
No Events
Events for 9th May
No Events
Events for 10th May
No Events
Events for 11th May
No Events
Events for 12th May
No Events
Events for 13th May
No Events
Events for 14th May
No Events
Events for 15th May
No Events
Events for 16th May
No Events
Events for 17th May
No Events
Events for 18th May
No Events
Events for 19th May
No Events
Events for 20th May
No Events
Events for 21st May
No Events
Events for 22nd May
No Events
Events for 23rd May
No Events
Events for 24th May
No Events
Events for 25th May
No Events
Events for 26th May
No Events
Events for 27th May
No Events
Events for 28th May
No Events
Events for 29th May
No Events
Events for 30th May
No Events
Events for 31st May
No Events